{"id":11520,"date":"2026-11-09T18:22:28","date_gmt":"2026-11-09T12:52:28","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-09\/"},"modified":"2026-11-09T18:22:30","modified_gmt":"2026-11-09T12:52:30","slug":"auropharma-share-price-today-2026-11-09","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-09\/","title":{"rendered":"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 2.84% | 9 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: AUROPHARMA<\/strong> \u00b7 9 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,855.30<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+2.84%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,856.10 \/ \u20b91,800.70<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,804.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>24.12 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>9 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Aurobindo Pharma Ltd shares advanced by 2.84% today, settling at \u20b91,855.30 against its previous close of \u20b91,804.00. The stock opened at \u20b91,810.60 and moved within a day&#x27;s range of \u20b91,800.70 to \u20b91,856.10, touching a new 52-week high during the trading session.<\/li>\n<li>Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, registering its highest ever quarterly revenue of \u20b910,263 crore, up 23.9% year-on-year. Quarterly net profit stood at \u20b91,124 crore, representing a 32.5% increase compared to the same period last year. The company also declared an interim dividend of \u20b97.00 per equity share with a record date of November 11, 2026.<\/li>\n<li>Trading volume was 2.28 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Aurobindo Pharma share price rising on 9 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Aurobindo Pharma Ltd shares advanced by 2.84% today, settling at \u20b91,855.30 against its previous close of \u20b91,804.00. The stock opened at \u20b91,810.60 and moved within a day&#x27;s range of \u20b91,800.70 to \u20b91,856.10, touching a new 52-week high during the trading session.<\/p>\n<p class=\"wt-copy\">The broader market and sector backdrop showed positive momentum, with the benchmark Nifty edging up by 0.06% while the Nifty Pharma sector index outperformed significantly, posting a gain of 3.42%. Aurobindo Pharma&#x27;s upward price action matches this strong sectoral tailwind, building on its recent performance trajectory that includes a 5-day return of 10.19% and a 20-day return of 9.59%.<\/p>\n<p class=\"wt-copy\">24.12 lakh shares traded by 9 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 10.59 lakh shares (2.28 times). The five-day average daily volume was 17.19 lakh shares. Separately, the NSE report for 9 November 2026 showed 13.82 lakh shares delivered, representing 57.31% of that day\u2019s traded volume. The same report recorded 120,364 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Strong sector tailwinds and robust cash volume participation following recent earnings momentum<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 2.84% gain and new 52-week high are supported by broad outperformance in the Nifty Pharma sector index, high trading volumes exceeding its 20-day average, and continuing positive sentiment from its strong Q2 FY27 earnings report announced earlier in the month.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Strong Q2 FY27 Financial Results and Record Revenue<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, registering its highest ever quarterly revenue of \u20b910,263 crore, up 23.9% year-on-year. Quarterly net profit stood at \u20b91,124 crore, representing a 32.5% increase compared to the same period last year. The company also declared an interim dividend of \u20b97.00 per equity share with a record date of November 11, 2026.<\/p>\n<p class=\"wt-copy\">Demonstrates sustained operational expansion across key global formulations and API segments, directly supporting baseline valuation metrics.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Internal Corporate Restructuring and Subsidiary Ownership Transfer<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board approved the transfer of ownership of Auro Pharma LLC in Russia from Auro Active Pharma Private Limited to Auropharm Overseas Limited for a cash consideration of approximately \u20b929 crore. Additionally, the board approved a proposal to merge Auroactive Pharma Private Limited into Apitoria Pharma Private Limited to consolidate API operations.<\/p>\n<p class=\"wt-copy\">Streamlines group corporate structure and optimizes capacity utilization across manufacturing subsidiaries.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Re-appointment of Independent Director M. R. Kumar<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board of directors approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director for a second term of five years commencing April 1, 2027, subject to shareholder approval via postal ballot. Mr. Kumar previously served as the Chairman of LIC of India.<\/p>\n<p class=\"wt-copy\">Secures continuity in governance and oversight from experienced leadership.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Corporate Actions This Week: HUL, Dabur, Balrampur Chini, Aurobindo Pharma, ONGC, Jyothy Labs, And Many More In Focus &#8211; NDTV Profit<\/div>\n<div class=\"wt-card-date\">8 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Corporate Actions This Week: HUL, Dabur, Balrampur Chini, Aurobindo Pharma, ONGC, Jyothy Labs, And Many More In Focus NDTV Profit<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated November 04, 2026, titled &quot;Press release on Q2 FY27 Financial Results.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">51.88%<\/div>\n<div class=\"wt-note\">51.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">17.41%<\/div>\n<div class=\"wt-note\">16.38% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">41.83%<\/div>\n<div class=\"wt-note\">41.48% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 44 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">QUANT MUTUAL FUND &#8211; QUANT ARBITRAGE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.83 crore shares \u00b7 4.91%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI NIFTY MIDCAP 150 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.02 crore shares \u00b7 3.51%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND-HDFC ARBITRAGE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.85 crore shares \u00b7 3.22%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Nuvama<\/div>\n<div class=\"wt-card-date\">23 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a positive outlook citing strong strategic positioning and market share expansion across key regulated geographies.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of the upcoming interim dividend record date scheduled for November 11, 2026<\/li>\n<li>Progress on the NCLT merger application involving Auroactive Pharma and Apitoria Pharma<\/li>\n<li>Integration milestones regarding the Lannett acquisition and new US product launches<\/li>\n<li>Sustained delivery percentage trends above the 50% threshold in subsequent trading sessions<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-05\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026 \u2014 5 November 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-23\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 2.43% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-22\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 1.41% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/auropharma\/\">More Aurobindo Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Aurobindo Pharma company news?<\/h3>\n<p class=\"wt-copy\">Aurobindo Pharma reported its financial results for the quarter ended September 30, 2026, registering its highest ever quarterly revenue of \u20b910,263 crore, up 23.9% year-on-year. Quarterly net profit stood at \u20b91,124 crore, representing a 32.5% increase compared to the same period last year. The company also declared an interim dividend of \u20b97.00 per equity share with a record date of November 11, 2026.<\/p>\n<h3>How strong was Aurobindo Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">24.12 lakh shares traded, 2.28 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-09\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-09\/\"}, \"headline\": \"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 2.84% | 9 November 2026\", \"description\": \"Aurobindo Pharma share price rose 2.84% to \u20b91,855.30 today. See why AUROPHARMA is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-09T18:22:18.289528+05:30\", \"dateModified\": \"2026-11-09T18:22:18.289528+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Aurobindo Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"AUROPHARMA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/auropharma-company-news-2026-11-09.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Corporate Actions This Week: HUL, Dabur, Balrampur Chini, Aurobindo Pharma, ONGC, Jyothy Labs, And Many More In Focus - NDTV Profit\",\"summary\":\"Corporate Actions This Week: HUL, Dabur, Balrampur Chini, Aurobindo Pharma, ONGC, Jyothy Labs, And Many More In Focus NDTV Profit\",\"source\":\"NDTV Profit\",\"published\":\"Sun, 08 Nov 2026 01:41:37 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false}],\"recent_news\":[{\"summary\":\"a press release dated November 04, 2026, titled \\\"Press release on Q2 FY27 Financial Results.\\\".\",\"category\":\"Press Release\",\"date\":\"04-Nov-2026 20:09:09\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"04-Nov-2026 19:53:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company.\",\"category\":\"Acquisition\",\"date\":\"04-Nov-2026 20:31:29\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026203119_LtrToSEsOwnershipTransferRussia04112026.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"a press release dated October 03, 2026, titled \\\"Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg\\\".\",\"category\":\"Press Release\",\"date\":\"03-Oct-2026 17:03:34\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_03102026170252_LtrToSEsPressReleasePerampanelUSFDAapproval03102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"UMBAI-400 051 Company Code No. AUROPHARMA Dear Sir I Madam, To The Corporate Relations Department SSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI-400 001 Company Code No. 524804 Sub: Disclosure of encumbrance pursuant to Reg. 31(4) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Pursuant to the applicable provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I, K. Nithyananda Reddy, one of the Promoters of the Company and on behalf of the other promoter and Promoter Group of the Company hereby declare that we have not made any encumbrance, directlyor indirectly, on the shares held by us in Aurobindo Pharma Limited, other than those already disclosed to the Stock Exchanges during the financial year ended on March 31,2026. I am enclosing herewith the list of promoters and promoter group of Aurobindo Pharma Limited without PAN as on March 31, 2026 Please take the information on record . Thanking you, Yours faithfully, \\\\L. __ - II K. NITHYANANDA REDDY AUTHORISED SIGNATORY (PROMOTRS & PROMOTER GROUP-AUROBINDO PHARMA LIMITED) Plot No 75 and 76, Huda EncLave B, Nandagiri Hills Jubilee Hi\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"19-Jun-2026 16:03:17\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_bbodade_11052026184659_AUROPHARMA.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":51.88,\"public_pct\":48.12,\"fii_pct\":17.41,\"dii_pct\":24.42,\"mf_pct\":16.31,\"institutional_pct\":41.83,\"noninst_pct\":6.29,\"mf_scheme_count\":44,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"QUANT MUTUAL FUND - QUANT ARBITRAGE FUND\",\"shares\":28265663,\"pct\":4.91},{\"name\":\"SBI NIFTY MIDCAP 150 INDEX FUND\",\"shares\":20175334,\"pct\":3.51},{\"name\":\"HDFC MUTUAL FUND-HDFC ARBITRAGE FUND\",\"shares\":18548115,\"pct\":3.22}],\"period\":\"30-SEP-2026\",\"submission_date\":\"14-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":51.88,\"previous_fii_pct\":16.38,\"previous_dii_pct\":25.1,\"previous_mf_pct\":16.71,\"previous_institutional_pct\":41.48,\"previous_mf_scheme_count\":42,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Nuvama\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why Business Today\",\"headline\":\"Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why\",\"published\":\"2026-06-23T07:00:00+00:00\",\"source\":\"Business Today\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma share price rose 2.84% to \u20b91,855.30 today. See why AUROPHARMA is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":11519,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 2.84% | 9 November 2026","_witty_meta_description":"Aurobindo Pharma share price rose 2.84% to \u20b91,855.30 today. See why AUROPHARMA is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Aurobindo Pharma share price today","_witty_reason_label":"Strong sector tailwinds and robust cash volume participation following recent earnings momentum","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[89],"class_list":["post-11520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-auropharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11520"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11520\/revisions"}],"predecessor-version":[{"id":11521,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11520\/revisions\/11521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11519"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}